Reduced Hospitalization Cost for Upper Gastrointestinal Events That Occur Among Elderly Veterans Who Are Gastroprotected

Neena Susan Abraham, Christine Hartman, Jennifer Hasche

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background & Aims: Despite prescription of gastroprotection among elderly nonsteroidal anti-inflammatory drug (NSAID) users, residual bleeding can still occur. We sought to determine the effect of proton pump inhibitors (PPI) on hospitalization and resource use among veterans in whom an upper gastrointestinal event (UGIE) occurred. Methods: We identified from national pharmacy records veterans ≥65 years prescribed an NSAID, cyclooxygenase-2 selective NSAID (coxib), or salicylate (>325 mg/day) at any Veterans Affairs (VA) facility (01/01/00-12/31/04). Prescription fill data were linked longitudinally to a Veterans Affairs-Medicare dataset of inpatient, outpatient, and death files, and demographic and provider data. Among veterans in whom a UGIE occurred, we assessed the effect of prescription strategy on hospitalization, using a multivariate logistic regression model. Results: A total of 3566 UGIEs occurred among a cohort that was predominantly male (97.5%), white (77%), with a mean age of 73.5 (SD, 5.7). Hospitalization occurred in 47.5%, and gastroprotection was associated with a 30% reduction in hospitalization compared with no PPI. Five-year pharmacy costs associated with the PPI strategy exceeded the no-PPI strategy ($742,406 vs $184,282); however, a substantial reduction in medical costs was observed with PPI ($9,948,738 vs $18,686,081). Conclusions: Even if an NSAID-UGIE occurs in the PPI-protected older veteran, the reduction in need for hospitalization results in a cost saving to the Department of Veterans Affairs.

Original languageEnglish (US)
Pages (from-to)350-356
Number of pages7
JournalClinical Gastroenterology and Hepatology
Volume8
Issue number4
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Veterans
Proton Pump Inhibitors
Hospitalization
Costs and Cost Analysis
Anti-Inflammatory Agents
Prescriptions
Logistic Models
Gastrointestinal Agents
Salicylates
Cyclooxygenase 2
Medicare
Drug Users
Pharmaceutical Preparations
Inpatients
Outpatients
Demography
Hemorrhage

Keywords

  • Administrative Database
  • Comparative Effectiveness
  • Department of Veterans Affairs
  • Gastrointestinal Hemorrhage
  • Health Resource Use

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Reduced Hospitalization Cost for Upper Gastrointestinal Events That Occur Among Elderly Veterans Who Are Gastroprotected. / Abraham, Neena Susan; Hartman, Christine; Hasche, Jennifer.

In: Clinical Gastroenterology and Hepatology, Vol. 8, No. 4, 04.2010, p. 350-356.

Research output: Contribution to journalArticle

@article{ef1f1c80887342d2b4600b3e4acf6e63,
title = "Reduced Hospitalization Cost for Upper Gastrointestinal Events That Occur Among Elderly Veterans Who Are Gastroprotected",
abstract = "Background & Aims: Despite prescription of gastroprotection among elderly nonsteroidal anti-inflammatory drug (NSAID) users, residual bleeding can still occur. We sought to determine the effect of proton pump inhibitors (PPI) on hospitalization and resource use among veterans in whom an upper gastrointestinal event (UGIE) occurred. Methods: We identified from national pharmacy records veterans ≥65 years prescribed an NSAID, cyclooxygenase-2 selective NSAID (coxib), or salicylate (>325 mg/day) at any Veterans Affairs (VA) facility (01/01/00-12/31/04). Prescription fill data were linked longitudinally to a Veterans Affairs-Medicare dataset of inpatient, outpatient, and death files, and demographic and provider data. Among veterans in whom a UGIE occurred, we assessed the effect of prescription strategy on hospitalization, using a multivariate logistic regression model. Results: A total of 3566 UGIEs occurred among a cohort that was predominantly male (97.5{\%}), white (77{\%}), with a mean age of 73.5 (SD, 5.7). Hospitalization occurred in 47.5{\%}, and gastroprotection was associated with a 30{\%} reduction in hospitalization compared with no PPI. Five-year pharmacy costs associated with the PPI strategy exceeded the no-PPI strategy ($742,406 vs $184,282); however, a substantial reduction in medical costs was observed with PPI ($9,948,738 vs $18,686,081). Conclusions: Even if an NSAID-UGIE occurs in the PPI-protected older veteran, the reduction in need for hospitalization results in a cost saving to the Department of Veterans Affairs.",
keywords = "Administrative Database, Comparative Effectiveness, Department of Veterans Affairs, Gastrointestinal Hemorrhage, Health Resource Use",
author = "Abraham, {Neena Susan} and Christine Hartman and Jennifer Hasche",
year = "2010",
month = "4",
doi = "10.1016/j.cgh.2010.01.002",
language = "English (US)",
volume = "8",
pages = "350--356",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Reduced Hospitalization Cost for Upper Gastrointestinal Events That Occur Among Elderly Veterans Who Are Gastroprotected

AU - Abraham, Neena Susan

AU - Hartman, Christine

AU - Hasche, Jennifer

PY - 2010/4

Y1 - 2010/4

N2 - Background & Aims: Despite prescription of gastroprotection among elderly nonsteroidal anti-inflammatory drug (NSAID) users, residual bleeding can still occur. We sought to determine the effect of proton pump inhibitors (PPI) on hospitalization and resource use among veterans in whom an upper gastrointestinal event (UGIE) occurred. Methods: We identified from national pharmacy records veterans ≥65 years prescribed an NSAID, cyclooxygenase-2 selective NSAID (coxib), or salicylate (>325 mg/day) at any Veterans Affairs (VA) facility (01/01/00-12/31/04). Prescription fill data were linked longitudinally to a Veterans Affairs-Medicare dataset of inpatient, outpatient, and death files, and demographic and provider data. Among veterans in whom a UGIE occurred, we assessed the effect of prescription strategy on hospitalization, using a multivariate logistic regression model. Results: A total of 3566 UGIEs occurred among a cohort that was predominantly male (97.5%), white (77%), with a mean age of 73.5 (SD, 5.7). Hospitalization occurred in 47.5%, and gastroprotection was associated with a 30% reduction in hospitalization compared with no PPI. Five-year pharmacy costs associated with the PPI strategy exceeded the no-PPI strategy ($742,406 vs $184,282); however, a substantial reduction in medical costs was observed with PPI ($9,948,738 vs $18,686,081). Conclusions: Even if an NSAID-UGIE occurs in the PPI-protected older veteran, the reduction in need for hospitalization results in a cost saving to the Department of Veterans Affairs.

AB - Background & Aims: Despite prescription of gastroprotection among elderly nonsteroidal anti-inflammatory drug (NSAID) users, residual bleeding can still occur. We sought to determine the effect of proton pump inhibitors (PPI) on hospitalization and resource use among veterans in whom an upper gastrointestinal event (UGIE) occurred. Methods: We identified from national pharmacy records veterans ≥65 years prescribed an NSAID, cyclooxygenase-2 selective NSAID (coxib), or salicylate (>325 mg/day) at any Veterans Affairs (VA) facility (01/01/00-12/31/04). Prescription fill data were linked longitudinally to a Veterans Affairs-Medicare dataset of inpatient, outpatient, and death files, and demographic and provider data. Among veterans in whom a UGIE occurred, we assessed the effect of prescription strategy on hospitalization, using a multivariate logistic regression model. Results: A total of 3566 UGIEs occurred among a cohort that was predominantly male (97.5%), white (77%), with a mean age of 73.5 (SD, 5.7). Hospitalization occurred in 47.5%, and gastroprotection was associated with a 30% reduction in hospitalization compared with no PPI. Five-year pharmacy costs associated with the PPI strategy exceeded the no-PPI strategy ($742,406 vs $184,282); however, a substantial reduction in medical costs was observed with PPI ($9,948,738 vs $18,686,081). Conclusions: Even if an NSAID-UGIE occurs in the PPI-protected older veteran, the reduction in need for hospitalization results in a cost saving to the Department of Veterans Affairs.

KW - Administrative Database

KW - Comparative Effectiveness

KW - Department of Veterans Affairs

KW - Gastrointestinal Hemorrhage

KW - Health Resource Use

UR - http://www.scopus.com/inward/record.url?scp=77949658275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949658275&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2010.01.002

DO - 10.1016/j.cgh.2010.01.002

M3 - Article

C2 - 20096378

AN - SCOPUS:77949658275

VL - 8

SP - 350

EP - 356

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 4

ER -